1902 related articles for article (PubMed ID: 24231131)
1. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.
Chau D; Becker DL; Coombes ME; Ioannidis G; Adachi JD; Goeree R
J Med Econ; 2012; 15 Suppl 1():3-14. PubMed ID: 23035625
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium.
Hiligsmann M; Reginster JY
Pharmacoeconomics; 2011 Oct; 29(10):895-911. PubMed ID: 21692551
[TBL] [Abstract][Full Text] [Related]
5. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
6. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.
Hiligsmann M; Reginster JY
Bone; 2010 Jul; 47(1):34-40. PubMed ID: 20303422
[TBL] [Abstract][Full Text] [Related]
7. Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective.
Silverman S; Agodoa I; Kruse M; Parthan A; Orwoll E
J Osteoporos; 2015; 2015():627631. PubMed ID: 26783494
[TBL] [Abstract][Full Text] [Related]
8. Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.
Scotland G; Waugh N; Royle P; McNamee P; Henderson R; Hollick R
Pharmacoeconomics; 2011 Nov; 29(11):951-61. PubMed ID: 21854080
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of denosumab for high-risk postmenopausal women with osteoporosis in Thailand.
Pongchaiyakul C; Nanagara R; Songpatanasilp T; Unnanuntana A
J Med Econ; 2020 Jul; 23(7):776-785. PubMed ID: 32063082
[No Abstract] [Full Text] [Related]
10. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
Albert SG; Reddy S
Endocr Pract; 2017 Jul; 23(7):841-856. PubMed ID: 28448754
[TBL] [Abstract][Full Text] [Related]
11. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
13. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis.
Jönsson B; Ström O; Eisman JA; Papaioannou A; Siris ES; Tosteson A; Kanis JA
Osteoporos Int; 2011 Mar; 22(3):967-82. PubMed ID: 20936401
[TBL] [Abstract][Full Text] [Related]
15. Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.
Ström O; Jönsson B; Kanis JA
Osteoporos Int; 2013 Apr; 24(4):1491-502. PubMed ID: 23224141
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan.
Mori T; Crandall CJ; Ganz DA
Osteoporos Int; 2017 May; 28(5):1733-1744. PubMed ID: 28210776
[TBL] [Abstract][Full Text] [Related]
17. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.
Murphy DR; Smolen LJ; Klein TM; Klein RW
BMC Musculoskelet Disord; 2012 Oct; 13():213. PubMed ID: 23110626
[TBL] [Abstract][Full Text] [Related]
18. Bridging the osteoporosis treatment gap: performance and cost-effectiveness of a fracture liaison service.
Yates CJ; Chauchard MA; Liew D; Bucknill A; Wark JD
J Clin Densitom; 2015; 18(2):150-6. PubMed ID: 25797867
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.
Schousboe JT; Taylor BC; Fink HA; Kane RL; Cummings SR; Orwoll ES; Melton LJ; Bauer DC; Ensrud KE
JAMA; 2007 Aug; 298(6):629-37. PubMed ID: 17684185
[TBL] [Abstract][Full Text] [Related]
20. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
Davis S; Martyn-St James M; Sanderson J; Stevens J; Goka E; Rawdin A; Sadler S; Wong R; Campbell F; Stevenson M; Strong M; Selby P; Gittoes N
Health Technol Assess; 2016 Oct; 20(78):1-406. PubMed ID: 27801641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]